Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach

  title={Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach},
  author={Stergios Boussios and Peeter Karihtala and Michele Moschetta and Charlotte Abson and Afroditi Karathanasi and Nikolaos Zakynthinakis-Kyriakou and Jake Edward Ryan and Matin Sheriff and Elie Rassy and Nicholas Pavlidis},
  journal={Investigational New Drugs},
Epithelial ovarian cancer (EOC) accounts for nearly 90% of all ovarian malignancies. The standard therapeutic strategy includes cytoreductive surgery and neo (adjuvant) platinum-based chemotherapy. Relapse of advanced high grade serous ovarian cancer (HGSOC) is related to the development of drug resistance. A defective DNA damage response is a defining hallmark of HGSOC. Poly (ADP-ribose) polymerase (PARP) inhibitors exploit this deficiency through synthetic lethality and have emerged as… 
Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
A comprehensive insight is provided into the most recent progress in synthetic lethality PARP inhibitors, along with the mechanisms of resistance in epithelial ovarian cancer.
Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
The mechanisms of DNA repair, synthetic lethality, efficiency of PARP inhibition, and an overview of early and ongoing clinical investigations of the novel PARP inhibitors veliparib and talazoparib are explored.
Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets
High-grade serous ovarian carcinoma is the most common type of ovarian cancer and the most lethal gynecologic malignancy due to advanced stage at presentation, and harnessing the immune system with combination therapies that promote antigen production and immune cell activation is an avenue being explored.
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
The scientific evidence that has emerged from both experimental and clinical studies in the development of talazoparib is discussed, and future directions will include optimizing combination therapy with chemotherapy, immunotherapies and targeted therapies, and in developing and validating biomarkers for patient selection and stratification, particularly in malignancies with ‘BRCAness’.
Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer.
The efficacy of niraparib has changed the landscape of ovarian cancer treatment, but overall survival data is still to come, as well as the mechanism of action, toxicities, single agent efficacy and novel combinations in ovarian cancer.
Veliparib for the treatment of solid malignancies
The results from clinical trials indicate that veliparib can be an excellent therapeutic strategy for BRCA mutation associated cancers and tumors bearing deficiencies in the HR pathway as well.
The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma
Niraparib and talazoparib were the most effective in reducing RCC xenograft growth in vivo and agents such as PARPi that exploit mutations in DNA damage repair genes may be effective therapeutic options for RCC.
Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know
PARP inhibitors can obtain an important role in making a personalized therapeutic program in the case of first-line, neoadjuvant, platinum-sensitive, and resistant high-grade serous OC treatment, including approved as well as currently investigated drugs.
Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
The current preclinical and clinical development of immunotherapy combination therapy to convert an immune cold tumor into a hot tumor and their underlying mechanisms are reviewed and the combination of anti-PD-1/PD-L1 with other immunomodulatory therapies, such as chemotherapy, antiangiogenic therapies, poly (ADP-ribose) polymerase inhibitors, adoptive cell therapy, and oncolytic therapy, could be beneficial.


PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
The aim of this review is to describe the current evidence for PARP inhibitors in ovarian cancer, their mechanism of action, and the outstanding issues, including the rate of long-term toxicities and the evolution of resistance.
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
It seems that PARP inhibitor and biologic agent combinations appear well tolerated and clinically effective in both BRCA-mutated and wild-type cancers, and overlapping myelosuppression observed with PARP inhibitors and chemotherapy combinations requires further investigation with dose escalation studies.
Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer
Novel mechanisms providing useful insights into DNA damage response (DDR) have been identified and alterations that render cells resistant to targeted therapies may cause new synthetic dependencies that can be exploited to combat resistant disease.
Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study
Treatment with veliparib in heavily pretreated patients with relapse of OC demonstrates a considerable efficacy with an acceptable toxicity profile.
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.
Niraparib is described, a potent PARP-1/2 inhibitor with good cell based activity, selectivity for cancer over normal cells, and oral bioavailability, and is currently being tested in phase 3 clinical trials as maintenance therapy in ovarian cancer and as a treatment for breast cancer.
Targeting DNA repair and replication stress in the treatment of ovarian cancer
  • J. Murai
  • Biology
    International Journal of Clinical Oncology
  • 2017
This review describes the rational basis for using DNA repair and DNA repair checkpoint inhibitors as single agents and presents the strategies combining these inhibitors with DNA damaging agents for ovarian cancer therapy based on specific gene alterations.
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
FATSI screening showed that a substantial number of patients' tumors have FA functional deficiency, which led to germline alterations in several patients's tumors, andVeliparib alone or with MMC was safely administered to these patients and produced clinical benefit in some, however, a better understanding of resistance mechanisms in this setting is needed.
Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
NU6027 inhibits ATR, impairing G2/M arrest and homologous recombination thus increasing sensitivity to DNA-damaging agents and PARP inhibitors and provides proof of concept data for clinical development of ATR inhibitors.
A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
Combined veliparib and LDFWAR is a well-tolerated regimen that resulted in prolonged disease stability for some patients with advanced solid tumors and carcinomatosis, particularly in the ovarian and fallopian cancer subpopulation.